Perampanel

Quick links to important sections

Perampanel

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Perampanel

What is Perampanel?

Perampanel is an anti-seizure medication used in the management of epilepsy. It belongs to a class of drugs known as selective, non-competitive antagonists of the AMPA glutamate receptor. By targeting these specific receptors in the brain, the medication helps to regulate nerve activity and reduce the occurrence of seizures.

Mechanism of Action

Glutamate is a primary excitatory neurotransmitter in the central nervous system. During a seizure, there is often excessive signaling through glutamate receptors. Perampanel works by binding to AMPA receptors on post-synaptic neurons, which prevents glutamate from over-stimulating these cells. This unique approach distinguishes it from many other anti-epileptic drugs that primarily target sodium channels or GABA receptors.

Therapeutic Use

Perampanel is utilized to treat different types of seizures, depending on the clinical presentation of the patient's epilepsy:

  • Focal-Onset Seizures: These are seizures that start in one specific area of the brain. Perampanel is used to manage these episodes, whether or not they spread to other parts of the brain.
  • Generalized Tonic-Clonic Seizures: These involve the entire brain and are characterized by muscle stiffening and rhythmic jerking. The medication is used as an adjunctive therapy to help control these primary generalized seizures.

Development and Classification

As a relatively recent addition to the epilepsy treatment landscape, perampanel represents a shift toward targeting specific neurochemical pathways involved in seizure generation. It is formulated to provide a long half-life, which allows for stable levels of the medication in the bloodstream over a 24-hour period.

What side effects are possible with Perampanel?

Possible Side Effects and Safety Information: Perampanel

The official safety profile of Perampanel, as documented by regulatory agencies, organizes potential adverse reactions into frequency categories and affected body systems. Understanding these classifications is key to appreciating the medicine's risk profile.

Adverse effects are often observed during the initial period of treatment, with common reactions like dizziness and somnolence being classified as Very Common in regulatory documents. Other common effects include headache, fatigue, and behavioral changes such as aggression, hostility, and irritability.

Safety Classifications

Classification Examples of Documented Adverse Reactions
Very Common Dizziness, Somnolence (Drowsiness)
Common Aggression, Ataxia, Irritability, Nausea, Weight gain, Blurred vision
Uncommon Suicide attempt, Suicidal ideation

Serious Adverse Reactions and Safety Constraints

Official labeling highlights the potential for serious behavioral and psychiatric reactions, including homicidal ideation and an increased risk of suicidal thoughts or behavior. A rare but severe systemic safety concern documented is Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Specific regulatory constraints exist for certain patient populations. The use of Perampanel is not recommended in patients with severe hepatic impairment or severe renal impairment/End-Stage Renal Disease (ESRD) on dialysis. Furthermore, the incidence of many adverse reactions is officially noted as being dose-related, meaning the frequency may increase with higher doses.

Overdose and Emergency Response

Regulatory documents characterize Perampanel overdose by the severe intensification of dose-related central nervous system (CNS) effects. Documented clinical manifestations include altered consciousness, stupor, profound dizziness, and gait disturbance leading to ataxia. These effects necessitate prolonged hospital observation due to the compound's notably long elimination half-life.

Overdose may also involve serious psychiatric and behavioral reactions. These include pronounced aggression, hostility, and the risk of homicidal or suicidal ideation, which are recognized as potentially life-threatening outcomes. This risk profile requires urgent intervention. For the elderly, CNS effects are amplified, increasing the risk of severe falls.

Official guidance mandates that individuals seek immediate medical attention for any suspected overdose. Emergency medical care is required immediately if severe CNS depression or protracted altered consciousness occurs, or if serious psychiatric and behavioral reactions are observed or worsen. The treatment of overdose is strictly symptomatic and supportive as no specific antidote is known. Continuous clinical monitoring is essential.

Therapeutic Uses of Perampanel

Quick Facts: Uses of Perampanel

  • Assists in managing focal-onset seizures (with or without focal to bilateral tonic-clonic seizures).
  • Contributes to the care of primary generalized tonic-clonic (PGTC) seizures.

What Perampanel Treats: Main Uses and Benefits

Perampanel is an established medication used to assist in the care of individuals diagnosed with epilepsy. It is indicated for the therapeutic management of several specific types of seizures.

The medication is used as an initial or single agent (monotherapy) and may also be utilized as an additional treatment (adjunctive therapy) alongside other anti-seizure medications. Its application is relevant for patients aged four years and older who experience focal-onset seizures. These seizures originate in a limited area of the brain and may or may not evolve into focal to bilateral tonic-clonic seizures.

Perampanel is also a suitable option as an add-on treatment for individuals aged twelve years and older who experience primary generalized tonic-clonic (PGTC) seizures. This type of seizure involves the entire brain from the onset and typically includes a loss of consciousness and full-body muscle contractions.

Through its approved use, perampanel helps in reducing seizure frequency, which may support improved seizure control for patients. The medication is utilized according to its established indications for these specific seizure types and patient age groups.

Eligibility and Restrictions for Use

Perampanel eligibility is strictly defined by regulatory guidelines, focusing on age, organ function, and pre-existing conditions.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Patients 4 years of age and older for Focal-Onset Seizures. Patients 12 years of age and older for Primary Generalized Tonic-Clonic (PGTC) Seizures
Populations for whom use is not recommended Patients with Severe Hepatic Impairment or Severe Renal Impairment. Pregnant women, as use is not recommended [Source 1.3, 1.7].
Populations for whom use is contraindicated Patients with known hypersensitivity to the drug or its excipients (non-US labeling). The US label formally states "None" as an absolute contraindication [Source 1.5, 1.6].

Age-Related and Conditional Rules

Category Official Regulatory Statement
Age-related eligibility rules Safety and effectiveness have not been established in children younger than 4 years for Focal-Onset Seizures, or younger than 12 years for PGTC Seizures [Source 2.7].
Condition-specific eligibility rules Use in Mild to Moderate Hepatic Impairment is restricted to a lower maximum daily dose [Source 1.7]. Use requires close monitoring for patients with a history of psychiatric or behavioral changes [Source 2.1].

The eligibility profile is structured by minimum age requirements specific to the seizure indication and formal exclusions for those with severe organ impairment. Use is also restricted by the requirement for effective contraception in women of childbearing potential, as stipulated by regulatory authorities [Source 1.3].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Perampanel is structured around pharmacokinetic and pharmacodynamic considerations, as documented in regulatory labeling.


Pharmacokinetic Interactions (Drug Exposure Changes)

Concomitant use with strong or moderate enzyme-inducing antiepileptic drugs (AEDs) significantly reduces the plasma concentration of perampanel. Specifically, Carbamazepine, Oxcarbazepine, and Phenytoin are explicitly listed as strong inducers that increase the clearance of perampanel, potentially decreasing its therapeutic effect. Regulatory documents mandate monitoring and potential adjustments to the perampanel dose when these inducers are introduced or withdrawn.

Conversely, perampanel itself may reduce the exposure of certain other medicines. At its highest regulated dose of 12 mg per day, perampanel can decrease the plasma levels of levonorgestrel, a component of some hormonal contraceptives, by approximately 40%. For this reason, official labeling recommends the use of an additional nonhormonal form of contraception when perampanel is co-administered with levonorgestrel-containing products.


Pharmacodynamic Interactions (Additive Effects)

Perampanel is associated with central nervous system (CNS) depressant effects. When combined with other CNS depressants, including ethanol (alcohol), the effects on complex tasks, vigilance, and alertness are additive or supra-additive. Official guidance states that patients should avoid alcohol and exercise caution regarding complex activities until they have experience with concomitant use of other CNS depressants.

Mechanism of Action

Selective Antagonism of AMPA Receptors

Perampanel's mechanism of action is focused on the glutamatergic system, the central excitatory pathway in the brain. The drug acts as a highly selective non-competitive antagonist of the postsynaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA receptors).

By binding to an allosteric site on the receptor, perampanel physically modulates the receptor's structure, preventing the ion channel from fully opening in response to the neurotransmitter glutamate. This molecular blockade reduces the rapid influx of positive ions, primarily sodium, into the neuron. The resulting decrease in postsynaptic depolarization lessens the efficacy of fast excitatory synaptic transmission. This cascade leads to a systemic attenuation of excitatory signal transmission across neuronal networks, which contributes to the modulation of network excitability within the central nervous system.

Dosage and Administration Information

Perampanel is administered solely via the oral route as a once-daily dose, typically taken at bedtime. The medication is available as film-coated tablets and an oral suspension. Tablets must be swallowed whole with water and should not be chewed, crushed, or split to ensure correct administration.


Official Dosing and Titration

Treatment for patients aged 12 years and older begins with a starting dose of 2 mg once daily. Dosing follows a structured titration pattern, increasing by increments of 2 mg no more frequently than at weekly intervals. The maintenance dose typically ranges from 8 mg to 12 mg daily, with 12 mg being the maximum recommended dose. However, a higher starting dose of 4 mg daily is used when the patient is concurrently taking certain enzyme-inducing antiepileptic drugs (AEDs).


Population and Procedural Constraints

The dosing regimen requires modification for specific patient populations. For individuals with mild or moderate hepatic impairment, the maximum dose is reduced (to 6 mg or 4 mg, respectively), and the titration interval is extended, proceeding no faster than every two weeks. Use is generally not recommended in patients with severe hepatic or severe renal impairment. In the event a patient misses multiple consecutive doses over an extended period, official instructions advise considering re-initiating treatment at the original starting dose and re-titrating.

Recent Clinical Evidence

Research evidence / Overview of studies for Perampanel

Evidence for Focal-Onset Seizures (FOS) in Adolescents and Adults

The primary research for Focal-Onset Seizures rests on several large-scale, Randomized Controlled Trials (RCTs). These studies were designed to evaluate Perampanel when it was added to existing anti-seizure medication regimens, primarily examining adolescents and adults whose seizures were continuing despite current treatment. Key outcomes were studied for changes in seizure frequency compared to placebo. Research highlights that the high-level evidence focuses on short-term outcomes because the core RCTs had limited follow-up durations. Evidence applies only to the populations studied, and research remains less characterized regarding its use as a single treatment (monotherapy).


Evidence for Primary Generalized Tonic-Clonic Seizures (PGTCS)

Research exploring Perampanel for Primary Generalized Tonic-Clonic Seizures (PGTCS) was evaluated in a single pivotal Randomized Controlled Trial (RCT). This trial focused specifically on patients with conditions involving periods of heightened symptoms related to Idiopathic Generalized Epilepsy (IGE), where Perampanel was observed in the adjunctive setting. The study data show patterns related to measured changes in PGTC seizure frequency compared to placebo. A limitation is the reliance on this single core RCT; consequently, long-term outcomes remain not fully established based on highly controlled data.


Evidence in Younger Children and Other Patient Groups

Research was examined in populations outside of the primary adult and adolescent groups, including studies down to age 4 for FOS and age 7 for PGTCS. Official research was studied for outcomes related to systemic or functional imbalance in these younger patient groups. However, for many severely affected children and other complex patient groups, data for certain subgroups remain insufficient when compared to the well-characterized adult trials.


Long-Term Studies and What is Still Uncertain

Beyond short-term trials, researchers have conducted Open-label Extension Studies (OLEx) and long-term observational research to monitor outcomes and retention over years. These studies provide context but not individual predictions, as they are evidence derived from settings that lack the strict comparison to placebo found in core RCTs. Furthermore, comparative evidence is lacking from trials that directly compare Perampanel against other anti-seizure medications. The results apply only to the populations studied, meaning research on its use as a first-line agent is less characterized.

Frequently Asked Questions (FAQ)

Common questions about Perampanel (FAQ)

Q: What is Perampanel used for?

A: Perampanel is an antiepileptic drug used in the treatment of certain types of seizures. It is indicated as an add-on treatment for focal-onset seizures with or without secondary generalization in patients aged 4 and older, and as an add-on treatment for primary generalized tonic-clonic seizures in patients aged 12 and older.

Q: How does Perampanel work?

A: Perampanel is thought to work by acting as a selective non-competitive antagonist of the AMPA receptor, a type of glutamate receptor in the brain. Glutamate is a chemical messenger that can excite nerve cells. By modifying the activity of the AMPA receptor, Perampanel may reduce the excessive neuronal excitability associated with seizures.

Q: What are common observations from clinical trials regarding Perampanel?

A: In clinical studies, the addition of Perampanel to existing anti-seizure regimens appeared to reduce seizure frequency in some patients with focal-onset or primary generalized tonic-clonic seizures, compared to a placebo group. The most frequently observed adverse events in trials included dizziness, somnolence, headache, and fatigue.

Q: Can Perampanel affect mood or behavior?

A: Clinical trial data suggests that Perampanel has been associated with changes in mood and behavior in some individuals, including reports of irritability, aggression, and hostility. Patients are typically monitored for the emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior while taking this medication.

Q: Are there important precautions to consider before taking Perampanel?

A: It is important for patients to inform their healthcare provider about their complete medical history, especially if they have a history of psychiatric problems, liver or kidney disease, or are pregnant or planning to become pregnant. Perampanel may cause dizziness or sleepiness, which suggests caution when performing activities requiring mental alertness, such as driving or operating heavy machinery.

How should Perampanel be stored and disposed of?

Storage and Disposal of Perampanel

The storage of Perampanel tablets and oral suspension must adhere to officially regulated conditions to ensure stability and safety.

Storage Requirements

  • Temperature: Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must not be frozen.
  • Protection: Keep the medicine away from excess heat, moisture, and direct light.
  • Container: Store in the original container with the cap tightly closed.

Stability and Safety

For the oral suspension, any unused portion must be discarded after 90 days from the date the bottle was first opened. Due to its classification as a controlled substance, Perampanel must be stored in a safe place and kept out of the reach and sight of children.

Disposal Instructions

Expired or unused Perampanel should not be disposed of in household trash or down the sink/toilet. Patients must consult a healthcare professional or pharmacist for instructions on using an authorized drug take-back program or other appropriate disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Perampanel found in:

A-Z Index: